Efficacy and Safety Assessment of T2345 in Ocular Hypertensive or Glaucomatous Patients

Thea Pharma

Status and phase: Completed; Phase 3

Conditions: Glaucoma

Treatments: Drug: Prostaglandin; Drug: T2345

Study type: Interventional

Funder types: Industry

Identifiers

NCT01156012

2009-011157-41 (EudraCT Number)

LT2345-PIII-12/08

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of T2345 versus active comparator.

Enrollment: 404 patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients diagnosed with glaucoma

Exclusion criteria

• Under 18.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

404 participants in 2 patient groups

T2345

Experimental group

Description:

One drop of T2345

Treatment:

Drug: T2345

Prostaglandin

Active Comparator group

Description:

One drop

Treatment:

Drug: Prostaglandin